News
Tallac announces first patient treated with TAC-001
Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumours.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumours.